Known dihydropyrimidine dehydrogenase (DPD) deficiency
Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency will be excluded
Known DPD (dihydro pyrimidine dehydrogenase) deficiency
Patients with history of positive dihydropyrimidine dehydrogenase (DPD) deficiency
Patient with known dihydropyrimidine dehydrogenase (DPD) deficiency
Known dihydropyrimidine dehydrogenase (DPD) deficiency or history of severe and unexpected reactions to fluoropyrimidine therapy in patients selected to receive capecitabine
Patients with a known dihydropyrimidine dehydrogenase (DPD) deficiency are ineligible
Known dihydropyrimidine dehydrogenase (DPD) deficiency
No known history of dihydropyrimidine dehydrogenase deficiency
Known dihydropyrimidine dehydrogenase deficiency
Known allergy to fluoropyrimidines or known dihydropyrimidine dehydrogenase (DPD) deficiency.
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Subject has known dihydropyrimidine dehydrogenase deficiency.
Patients with known dihydropyrimidine dehydrogenase deficiency
Known dihydropyrimidine dehydrogenase deficiency
Has known dihydropyrimidine dehydrogenase deficiency (DPD) deficiency (testing not required)
Known homozygous DPD (dihydro pyrimidine dehydrogenase) deficiency
Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency
Contraindications or history of allergic reaction to lapatinib or to capecitabine, known dihydropyrimidine dehydrogenase deficiency, or known hypersensitivity of -fluorouracil
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Has a known DPD deficiency
Known hypersensitivity to -fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiency
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Has known dihydropyrimidine dehydrogenase deficiency (DPD) deficiency (testing not required)
Known dihydropyrimidine dehydrogenase (DPD) deficiency or severe renal impairment (creatinine clearance <  mL/min by Cockcroft-Gault formula)
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Known dihydropyrimidine dehydrogenase deficiency
Patients with known deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme
Prior systemic fluoropyrimidine therapy; prior topical fluoropyrimidine use is allowed; prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to -fluorouracil or known dihydropyrimidine dehydrogenase deficiency (DPD) deficiency
Prior systemic fluoropyrimidine therapy (unless given in an adjuvant setting and completed at least  months earlier); prior topical fluoropyrimidine use is allowed; prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to -fluorouracil (fluorouracil) or known dihydropyrimidine dehydrogenase (DPD) deficiency
Known hypersensitivity to capecitabine, temozolomide, or any component of the formulation and or a known deficiency of dihydropyrimidine dehydrogenase
Prior systemic fluoropyrimidine therapy (unless given in an adjuvant setting and completed at least  months earlier); prior topical fluoropyrimidine use is allowed; prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to -fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiency
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (-FU), or ruxolitinib, or any of their excipients.
No prior history of:\r\n* Congestive heart failure (New York Heart Association [NYHA] class I to IV)\r\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency
Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (-FU), ruxolitinib, or any of their excipients.
Known deficiency of dihydropyrimidine dehydrogenase (DPD)
Known dihydropyrimidine dehydrogenase deficiency or thymidylate synthase gene polymorphism predisposing the patient for -FU toxicity
Patient must not have known dihydropyrimidine dehydrogenase (DPD) deficiency or severe renal impairment (creatinine clearance below  mL/min by Cockcroft and Gault formula) as this would prelude use of capecitabine
Has a known dihydropyrimidine dehydrogenase deficiency
Known DPD deficiency;
Known dihydropyrimidine dehydrogenase deficiency
Patients with dihydropyrimidine dehydrogenase (DPD) deficiency
Known dihydropyrimidine dehydrogenase (DPD) deficiency. Testing for DPD deficiency must be performed where required by local regulations, using a validated method that is approved by local health authorities.
